Gerresheimer has announced investments to rapidly expand its manufacturing, supply and logistics capability for glass vials in the US. The project will be supported by the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the US Department of Health and Human Services (HHS) with contracting support from the Department of Defense (DOD). BARDA has agreed to provide up to approximately $66 million for this project.

Under the agreement, Gerresheimer will increase its annual production capacity in Morganton, NC with interchangeable Type 1 vials (glass borosilicate and/or aluminosilicate) and Gx Elite Glass Vials capability. BARDA’s financing will strengthen the capabilities in the US to respond to current and future public health emergencies. The vials can be used in vaccination campaigns against infectious diseases, such as COVID-19 and others.

As part of the project, the existing facility in North Carolina will be enlarged by the installation of new vial forming lines and a new warehouse. As the investment will lead to an increase in the number of people employed, new offices will also be part of the expansion plan.

The company is committed to sourcing the vast majority of its raw materials from US domestic suppliers in order to enhance the levels of responsiveness, dependability, quality and domestic supply chain integration. Gerresheimer is furthermore incorporating sustainable design principles to implement energy efficiency measures, comply with storm water management requirements and reduce waste for the upgrades and expansion.

www.gerresheimer.com

Image: US government supports Gerresheimer investment in North Carolina expansion.